COST-EFFECTIVENESS OF DIMETHYL FUMARATE TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS FROM A DANISH PERSPECTIVE

被引：3
|
作者：
Olsen, J. [1 ]
Wiren, A. [2 ]
机构：
[1] HOLTE, Incent Aps, Copenhagen, Denmark
[2] Biogen Denmark AS, Copenhagen, Denmark
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2469
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND54
引用
收藏
页码：A758 / A758
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Baharnoori, Moogeh
    Bhan, Virender
    Clift, Fraser
    Thomas, Kimberly
    Mouallif, Soukaina
    Adlard, Nicholas
    Cooney, Philip
    Blanchette, Francois
    Patel, Barkha P.
    Grima, Daniel
    PHARMACOECONOMICS-OPEN, 2022, 6 (06) : 859 - 870
  • [32] Treatment patterns in the use of dimethyl fumarate in relapsing-remitting multiple sclerosis in Denmark A Danish nationwide cohort study
    Magyari, M.
    Buron, M.
    Joensen, H.
    Kopp, T. Iskov
    Rasmussen, P. V.
    Blinkenberg, M.
    Sorensen, P. S.
    Sellebjerg, F.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 518 - 519
  • [33] THE COST-EFFECTIVENESS OF DELAYED-RELEASE DIMETHYL FUMARATE VERSUS GLATIRAMER ACETATE FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE CHILEAN NATIONAL HEALTH FUND (FONASA)
    Noda, C.
    de Anda, J. A.
    Anaya, P.
    Serafini, P.
    Machado, M.
    VALUE IN HEALTH, 2016, 19 (07) : A431 - A431
  • [34] Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
    Boullosa-Lale, Silvia
    Gonzalez-Freire, Lara
    Martinez-Martinez, Luciano
    Crespo-Diz, Carlos
    FARMACIA HOSPITALARIA, 2021, 45 (02) : 73 - 76
  • [35] Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
    Johannes Lorscheider
    Pascal Benkert
    Carmen Lienert
    Peter Hänni
    Tobias Derfuss
    Jens Kuhle
    Ludwig Kappos
    Özgür Yaldizli
    Journal of Neurology, 2021, 268 : 941 - 949
  • [36] The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
    Bozkaya, Duygu
    Livingston, Terrie
    Migliaccio-Walle, Kristen
    Odom, Tanner
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 297 - 302
  • [37] Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia
    Lasalvia, Pieralessandro
    Hernandez, Fabian
    Castaneda-Cardona, Camilo
    Andres Cuestas, J.
    Rosselli, Diego
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 23 : 13 - 18
  • [38] A COST-EFFECTIVENESS ANALYSIS OF FINGOLIMOD VERSUS DIMETHYL FUMARATE AS A SECOND-LINE DISEASE MODIFYING TREATMENT IN PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Raikou, M.
    Kalogeropoulou, M.
    Rombopoulos, G.
    VALUE IN HEALTH, 2015, 18 (07) : A758 - A758
  • [39] COST-EFFECTIVENESS OF NATALIZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN RUSSIA
    Matveev, N., V
    Sabanov, A., V
    Luneva, A., V
    VALUE IN HEALTH, 2014, 17 (03) : A60 - A60
  • [40] Cost-Effectiveness of Fingolimod in Treating Patients With Relapsing-Remitting Multiple Sclerosis
    Agashivala, Neetu V.
    Dastani, Homa B.
    Carlton, Rashad
    Sarnes, Evelyn
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2011, 3 (06) : 320 - 328
12345